Showing 1,521 - 1,540 results of 1,840 for search '"clinical research"', query time: 0.09s Refine Results
  1. 1521
  2. 1522
  3. 1523

    Ivermectin as a promising therapeutic option for onchocerciasis‐associated epilepsy by Mohammad Amin Manavi, Razieh Mohammad Jafari, Hamed Shafaroodi, Mohammad Sharifzadeh, Ahmad Reza Dehpour

    Published 2025-02-01
    “…About one third of Ugandan patients saw reduced seizure frequency or intensity after one 150 μg/kg dose. Clinical research in the Congo among infected epileptics on anti‐seizure medications (ASMs) suggested ivermectin may decrease seizure frequency following oral administration of ivermectin tablets (3 mg). …”
    Get full text
    Article
  4. 1524
  5. 1525
  6. 1526
  7. 1527
  8. 1528

    Treatment of Proximal Humeral Fractures in Older Patients During COVID-19 Pandemic in Germany by Sußiek J, Koeppe J, Fischhuber K, Iking J, Marschall U, Raschke MJ, Katthagen JC, Stolberg-Stolberg J

    Published 2025-01-01
    “…Julia Sußiek,1,* Jeanette Koeppe,2,3,* Karen Fischhuber,2,3 Janette Iking,1,3 Ursula Marschall,4 Michael J Raschke,1 J Christoph Katthagen,1,3 Josef Stolberg-Stolberg1,3 1Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital Muenster, Muenster, Germany; 2Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany; 3Research Group “Mathematical Surgery”, University Hospital Muenster, University of Muenster, Muenster, Germany; 4Department of Medicine and Health Services Research, BARMER Health Insurance, Wuppertal, Germany*These authors contributed equally to this workCorrespondence: Josef Stolberg-Stolberg, Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building W1, Muenster, 48149, Germany, Tel +49 251 83 59231, Email josef.stolberg-stolberg@ukmuenster.dePurpose: The COVID-19 pandemic had a severe influence on the entire health sector. …”
    Get full text
    Article
  9. 1529
  10. 1530

    Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases by Marilena Durazzo, Arianna Ferro, Victor Manuel Navarro-Tableros, Andrea Gaido, Paolo Fornengo, Fiorella Altruda, Renato Romagnoli, Søren K. Moestrup, Pier Luigi Calvo, Sharmila Fagoonee

    Published 2025-01-01
    “…Further, we describe how this knowledge is linked to current molecular therapies as well as ongoing preclinical and clinical research on novel targeting strategies, including nucleic acid-, mesenchymal stromal/stem cell-, and extracellular vesicle-based options. …”
    Get full text
    Article
  11. 1531
  12. 1532
  13. 1533

    Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol by Lisa Kuramoto, Larry D Lynd, Amir Khakban, Jacquelyn J Cragg, Anthony Traboulsee, Jiwon Oh, Analisa Jia, Weng Sut Sio, M A De Vera, Jonathan Loree, Roger Tam

    Published 2025-01-01
    “…Survival analysis will be used to estimate HRs and corresponding 95% CIs, adjusted for potential confounders.Ethics and dissemination Ethics approval for this study was obtained from the University of British Columbia Clinical Research Ethics Board (H24-03199). No personal identifying information will be made available as part of this study. …”
    Get full text
    Article
  14. 1534
  15. 1535
  16. 1536
  17. 1537
  18. 1538
  19. 1539
  20. 1540